BMS-684

CAS No. 313552-29-3

BMS-684( —— )

Catalog No. M37108 CAS No. 313552-29-3

BMS-684 is a selective and potent DGKα inhibitor (IC50: 15 nM) with potential antitumor activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 219 In Stock
10MG 352 In Stock
25MG 562 In Stock
50MG 736 In Stock
100MG 995 In Stock
200MG 1321 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    BMS-684
  • Note
    Research use only, not for human use.
  • Brief Description
    BMS-684 is a selective and potent DGKα inhibitor (IC50: 15 nM) with potential antitumor activity.
  • Description
    BMS-684 is a selective DGKα inhibitor with an IC50 of 15 nM. BMS-684 inhibits DGKα kinase activity with >100-fold selectivity over the related DGK type I family members DGKβ and DGKγ. BMS-684 does not inhibit any of the other seven DGK isozymes.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    313552-29-3
  • Formula Weight
    454.52
  • Molecular Formula
    C27H26N4O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C1C([N+]([O-])=O)=C(N2CCN(C(C3=CC=CC=C3)C4=CC=CC=C4)CC2)C5=C(N1C)C=CC=C5
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Michael Wichroski, et al. DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell-mediated antitumor immunity. Sci Transl Med. 2023 Oct 25;15(719):eadh1892. ?
molnova catalog
related products
  • AGX51

    AGX51 is an antagonist of inhibitor of DNA binding (ID) proteins. AGX51 treatment lead to pan-Id degradation, cell cycle arrest, and cell death.

  • Heliotrine N-oxide

    Heliotrine N-oxide is the pyrrolizidine alkaloid (PA) N-oxide counterpart of Heliotrine. It induces the generation of pyrrolic DNA adducts, potentially initiating PA-induced liver tumors in vivo.

  • CNX-1351

    CNX-1351 is a potent and isoform-selective targeted covalent PI3Kα inhibitor.